Quince Therapeutics, Inc. QNCX 深 滬
等待開盤 02-10 09:30:00 美东时间
0.13
-0.009
-6.54%
華盛通- 最 高0.1463
- 今 開0.14
- 成交量 289.21万股
- 最 低 0.1251
- 昨 收 0.1391
- 總市值 723.86万
- 52周最高 4.5499
- 市盈率 靜 --
- 換手率 5.19%
- 52周最低 0.1251
- 委 比 82.17%
- 總股本 5568.15万
- 歷史最高 121.98
- 量 比 0.44
- 振 幅 15.24%
- 歷史最低 0.1251
- 每 手 1
- 風險率 0.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Quince Therapeutics To Explore Strategic Alternatives, Appoints LifeSci Capital As Financial Adviser
Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives aimed at
3分钟前
Quince Therapeutics Announces Significant Board of Directors Resignations
An update from Quince Therapeutics ( ($QNCX) ) is now available. On January 30,...
02-03 06:11
Five Directors Resign from Quince Therapeutics Board
Five Directors Resign from Quince Therapeutics Board Quince Therapeutics Inc. announced that Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray have resigned from the company's board of directors, effective January 30, 2026. The company stated that the resignations were not due to
02-03 05:31
D. Boral Capital Downgrades Quince Therapeutics to Hold
D. Boral Capital analyst Jason Kolbert downgrades Quince Therapeutics (NASDAQ:QNCX) from Buy to Hold.
01-30 20:45
美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
01-30 17:38
Quince Therapeutics Announced The Poster Presentation From The Long-term Treatment Of Children With Ataxia-Telangiectasia At The British Paediatric Neurology Association 2026 Annual Meeting; Long-term Treatment With eDSP In Children With A-T Was Associated With Stable Growth And Metabolic Parameters Without Indications Of Corticosteroid-Related Toxicities
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of
01-29 05:30
Quince Therapeutics Reports Long-Term Safety Data for eDSP in Children with Ataxia-Telangiectasia
Quince Therapeutics Reports Long-Term Safety Data for eDSP in Children with Ataxia-Telangiectasia Quince Therapeutics Inc. announced the presentation of previously published safety data from long-term treatment with encapsulated dexamethasone sodium phosphate (eDSP) in children with Ataxia-Telangiec
01-29 05:06
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Quince Therapeutics Says Last Patient Completed Last Visit In Pivotal Phase 3 NEAT Clinical Trial Of eDSP, In Patients With Ataxia-Telangiectasia; Expects To Report Topline Results From In Q1 2026
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the last patient has
2025-12-15 21:07
Catalyst Watch: Holiday shopping data, Amazon event, and Salesforce earnings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - December ...
2025-11-29 02:30
